PLSE | Pulse Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	15.82 - 17.19
52 Week Range	6.51 - 22.69
Beta	2.03
Implied Volatility	53.68%
IV Rank	23.62%
Day's Volume	160,935
Average Volume	167,853
Shares Outstanding	61,516,700
Market Cap	992,879,538
Sector	Healthcare
Industry	Medical - Instruments & Supplies
IPO Date	2016-05-18

Valuation
Profitability
Growth
Health
P/E Ratio	-19.45
Forward P/E Ratio	N/A
EPS	-0.83
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	56
Country	USA
Website	PLSE

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.

PLSE's peers: INFU, KRMD, MLSS, PDEX, OSUR, NYXH, LMAT, UTMD, AKYA, ATRC, ATRI, ICUI, HAE

*Chart delayed

Analyzing fundamentals for PLSE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is strong. For more detailed analysis please see PLSE Fundamentals page.

Watching at PLSE technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on PLSE Technicals page.